Health Care–Associated Infections:
Is There an End in Sight?

Lisa Sprague, Principal Policy Analyst
OVERVIEW — Health care-associated infections (HAIs) have

emerged as a significant concern in policy as well as clinical
circles. An HAI is an infection acquired during treatment for
another condition. Some of the HAI-causing bacteria have
become drug-resistant; methicillin-resistant Staphylococcus
aureus, or MRSA, is a familiar example. Tied to perhaps

100,000 deaths and $20 billion in health care costs each year,
HAIs have given rise to state laws, legislative proposals at the
federal level, public-private initiatives, and work at the hospital
system and individual hospital level. However, much remains
to be done. This issue brief reviews the prevalence of HAIs
and the strategies for and barriers to reducing their incidence.
It examines the roles of public- and private-sector entities in
reporting, monitoring, and eliminating HAIs. Policy responses
such as research funding, training specifications, and payment
adjustments are considered.

ISSUE BRIEF

No. 830

March 13, 2009

March 13, 2009

National Health Policy Forum
2131 K Street, NW
Suite 500
Washington, DC 20037
T 202/872-1390
F 202/862-9837
E nhpf@gwu.edu
www.nhpf.org
Judith Miller Jones
Director
Sally Coberly, PhD
Deputy Director
Monique Martineau
Publications Director

National Health Policy Forum

A

ccounts in the popular press tend to have similar beginnings: Jane or John goes into the hospital for a routine procedure, gets an infection, and has to stay for a week
instead of overnight. Or loses a limb. Or, in the grimmer
versions, dies. “Superbug” is the term often applied to the
infecting agent, such as a Staphylococcus bacterium (for example methicillin- resistant Staphylococcus aureus, or MRSA),
that has proved resistant to standard antibiotics and threatening to the patient’s life.
In policy as well as clinical circles, health care-associated infections,
HAIs (sometimes called hospital-acquired infections) have emerged
as a significant concern. The Centers for Disease Control and Prevention (CDC) estimated that 1.7 million HAIs occurred in U.S. hospitals
in 2002 and were associated with approximately 99,000 deaths.1 A
Department of Health and Human Services (HHS) news release suggests that HAIs add as much as $20 billion to the nation’s health care
tab each year.2
Many efforts are under way to address the HAI problem. Twentysix states have passed HAI-related laws, mostly having to do with
public reporting of infections. Local and national hospital groups,
infection control professionals, and epidemiologists have undertaken infection-prevention initiatives, with some impressive success
stories. Several pieces of HAI-related legislation have also been introduced at the federal level. The Centers for Medicare & Medicaid Services (CMS) in October 2008 suspended payment for additional costs
for treatment of certain “reasonably preventable” HAIs (see further
discussion, page 8). In January 2009, HHS announced an Action Plan
to Prevent Healthcare-Associated Infections, whereby CDC, CMS,
the Agency for Health Care Research and Quality (AHRQ), and other federal agencies will coordinate efforts to reduce HAIs.
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It is clear that preventing infections is no small task. A 2007 survey by
the Leapfrog Group (an employer-backed group focused on hospital
quality) found that 87 percent of U.S. hospitals have failed to implement recommended guidelines to prevent avoidable infections.3 A
survey by the Association for Professionals in Infection Control &
Epidemiology (APIC) revealed that more than half of respondents
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judged their hospitals were not doing as much as they could to prevent the spread of MRSA.4 Infection preventionists report that they
have struggled all along to garner sufficient hospital resources and
top management attention to support prevention efforts.
This issue brief reviews the prevalence of HAIs, the strategies for controlling them, and the barriers—technical, practical, and human—to
their elimination. It reviews the roles of public- and private-sector
entities in monitoring, reporting, and reducing the incidence of infection, and considers further policy development in these areas.

W hat is a n H A I ?
In simplest terms, an HAI is an infection acquired during treatment—
most often but not necessarily in a hospital—for another condition.
HAIs may be caused by bacteria, fungi or viruses. The infections
often occur in connection with a device, such as catheter or a ventilator. Additionally, pathogens may be spread by touch or ingestion, or
via a contaminated needle or other item of medical equipment. Some
patients who carry bacteria into a hospital may be “colonized,” that
is, carrying pathogens without being actually infected, yet still able
to spread the germ that could become an infection in other people
or themselves. For example, MRSA can live asymptomatically in the
nose or throat of a healthy person. People already weakened by other diseases or the treatments thereof, along with the very young and
very old, are most vulnerable to harm.
As recently categorized by a group of health care organizations
closely concerned with the topic, the most significant HAIs are those
associated with devices and procedures (central line–associated
bloodstream infection, ventilator-associated pneumonia, catheterassociated urinary tract infection, surgical site infection) and those
attributable to specific organisms, such as MRSA and Clostridium difficile (or C. diff.). 5
Not all infections are contracted in a health care setting, certainly.
While a surgical site infection is unlikely to occur in the course of
daily life, and C. diff. is generally transferred among nursing home and
hospital patients, cases of MRSA among people with no links to recent health care delivery have increased in recent years. Communityassociated MRSA (CA-MRSA for short, a different strain of the MRSA
bacterium6 from health care–associated, HA-MRSA) is known to
3
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spread in crowded settings, where there is close skin-to-skin contact, during activities that result in abraded or compromised skin
surfaces, and when potentially contaminated personal items such as
towels and sporting equipment are shared. In short, prisons, gyms,
locker rooms, and day care are fine breeding grounds. For the most
part, CA-MRSA manifests as uncomplicated skin and soft tissue infection that can usually be treated with commonly available antimicrobial agents.
Eighty-five percent of the serious (that is, invasive) MRSA cases identified by CDC in the period July 2004 to December 2005 were associated with health care. Moreover, among the more than 18,000
people who died as a result of MRSA in that period, 92 percent had
HA-MRSA infections.7
Treatment of bacterial infections usually requires a prescription antibiotic. While created to destroy harmful bacteria, antibiotics lose
their effectiveness over time as resistance develops in the bacterial
population. Antibiotic resistance is a microscopic illustration of the
dictum, “What doesn’t kill you makes you stronger,” as well as of
basic natural selection. A bacterium with a genetic mutation that allows it to survive the antibiotic that wipes out most of its kin is the
one that will be able to reproduce, passing on its immunity until this
becomes the norm in succeeding generations. The more that antibiotics are prescribed, the more opportunities for resistance to develop. This is the basis for concern about over-prescribing, particularly
in cases (such as the virus-caused common cold) where an antibiotic
can effect no cure, except perhaps by means of the placebo effect on
patients who want something done for them.

Pre v en t i o n a n d Era dicat i o n
Keeping HAIs at bay begins with basic hygiene: washing hands,
cleaning surfaces that a colonized or infected person may have
touched or coughed on, and refraining from inappropriate re-use
of supplies and equipment, such as syringes and needles. Hospitals
have also begun focusing on reducing the bacteria adhering to a
person’s skin, especially before surgery, by means of washing the
patient with a fast-acting antiseptic such as chlorhexidine.
Hand-washing, which seems such a simple precaution, is actually an
ongoing problem for hospitals and other care facilities. Patient rooms
4
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may not have sinks. A busy clinician may semi-consciously think,
“I just washed my hands,” failing to register subsequent touches of
potentially contaminated surfaces. CDC stresses that hand hygiene
should be adhered to in conjunction with environmental hygiene
and other appropriate infection control practices.
Isolation and barriers are the next line of defense. CDC guidelines
suggest that in the allocation of available single-patient rooms, priority be given to patients with conditions that “facilitate transmission
of infectious material to other patients” (such as draining wounds or
incontinence) and to those at heightened risk of acquisition and adverse outcomes related to an HAI.8 Gloves, gowns, and masks offer
protection to health care personnel and visitors
and may interrupt transmission of organisms
to other patients.

Eighty-five percent of the serious
MRSA cases identified by CDC between
July 2004 and December 2005 were
contracted in health care settings.

On-admission screening of patients for MRSA
or other bacteria that cause HAIs is one strategy that hospitals may use along with other
elements of infection prevention. Whether
widespread implementation is called for is not
certain. CDC notes that screening is only useful if the necessary next steps can be provided, including isolation at
least until screening results are available and possibly for the duration of infection or colonization, and decolonization for some bacteria. Veterans Affairs Health Administration hospitals and some other
hospital systems now screen all admitted patients for MRSA. Legislation has been proposed in several states, and enacted in Illinois,
Pennsylvania, New Jersey, and California, to require all-admission
screening for MRSA. New present-on-admission (POA) reporting requirements instituted by CMS (discussed below) certainly nudge all
hospitals in this direction, although, some contend, not necessarily
to the advantage of the patient.
Research published in The Journal of the American Medical Association
in 2008 found that universal screening did not reduce nosocomial
(hospital-acquired) MRSA infections in a surgical department.9 A
pair of physicians commenting on that research point out that much
of the data supporting all-admission screening came from single
hospitals using multiple interventions during MRSA outbreaks,
without concurrent control groups as a means of demonstrating that
screening was the key variable. (For example, researchers evaluating
a program at Evanston Northwestern Healthcare hospitals found
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that universal screening combined with other precautions was associated with a reduction in the incidence of MRSA infections in the
hospital and 30 days after discharge.10) The physician commenters
also note that isolating more patients on the basis of screening potentially subjects a larger group to the risk of reduced attention from
health care workers and increased rates of depression and anxiety.11
Electronic surveillance may hold promise as a way of dealing with
HAIs. Systems such as MedMined and TheraDoc analyze data from
admissions and discharges as well as patterns of antibiotic ordering
to reveal infection clusters and to address the antibiotic overuse that
encourages the development of resistance. Proponents cite the ability
to sort data by facility, unit, organism, or lab test. Vendors suggest that
the initial $100,000 to $300,000 investment may be recouped speedily
through the reduction of unreimbursed costs related to infection.12 A
survey of 790 hospital clinicians by the Premier healthcare alliance
found that 22 percent of respondents used such a system, and 47
percent were considering a purchase.13
Some have adopted a less technological approach to infection control: the checklist. Peter Pronovost, MD, and colleagues designed
an intervention based on recommendations in CDC guidelines to
educate clinicians in the use of five evidence-based best practices for
reducing the risk of catheter-related bloodstream infections and to
track their subsequent adherence to these practices. The five procedures are hand-washing, using full-barrier precautions during the
insertion of central venous catheters, cleaning the skin with chlorhexidine, avoiding the femoral site if possible, and removing unnecessary catheters. Implemented in 103 intensive care units in Michigan
hospitals in 2004, the intervention resulted in a median infection rate
of 0.0 per 1,000 catheter days (from 2.7) within three months.14 A compendium of strategies to prevent HAIs in acute care hospitals issued
by the five health care organizations referenced above (see endnote
5) similarly takes an education-and-basic-steps approach.

Rep o rt i n g H A I s
Two agencies within HHS maintain data on HAIs. CDC’s National
Healthcare Safety Network (NHSN) has over 2,100 health care facilities enrolled in 48 states, many of which voluntarily report data
on HAIs associated with medical devices, medical procedures, or
related to antimicrobial resistance. Efforts are under way at CDC to
6
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streamline HAI data collection by enabling health care facilities to
use data already available in electronic form at their facilities as the
basis for reporting to NHSN. AHRQ’s Healthcare Cost and Utilization Project (HCUP) collects discharge data (including discharges
following HAIs) reported by hospitals in 39 voluntarily participating states. As the Government Accountability Office pointed out in
a recent report, limitations in the scope and data collection methods
mean that currently these databases do not generate a national estimate of all HAIs associated with medical devices.15
Thanks in part to the efforts of the Consumers Union’s
Stop Hospital Infections initiative, 26 states require some Electronic surveillance may hold promise
form of public reporting of HAIs by health care facilities. as a way of dealing with HAIs.
Pennsylvania was a pioneer; its Health Care Cost Containment Council (PHC4) began reporting infection rates by
hospital in 2005. Legislation enacted in 2007 made Pennsylvania also
the first state to implement reporting by nursing homes. Many states
specify that hospitals shall report via the NHSN, which means that
reporting is financed with federal dollars (characterized by some as
an unfunded mandate in reverse).

Educat i n g , M o n i to ri n g , En f o rci n g :
t he Play ers
In addition to maintaining the databases described above, several
agencies within HHS have responsibilities with respect to infection control. CDC is central to education, research, and guideline
development. It partners with other agencies and groups such as the
Institute for Healthcare Improvement, Medicare’s Quality Improvement Organization contractors, and hospital associations to promote
consumer and clinician awareness and to spur adoption of guidelines. Five academic partners funded by CDC have been designated
Prevention Epicenters; their current focus is “to find novel strategies
for detection and prevention of post-surgical adverse events, bloodstream infections, Clostridium difficile infections, infections caused by
antimicrobial-resistant organisms, and inappropriate antimicrobial
use.”16 However, CDC’s role is informational and persuasive; it has
no enforcement authority over health care providers. AHRQ, like
CDC, is involved in research, guideline development, and education
related to HAIs.
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CMS, as the payer for Medicare services, potentially has significant
leverage over hospitals and other providers. A recent illustration
is the inclusion of certain infections in a list of conditions for the
treatment of which pay will be limited. New reporting requirements
have also been imposed. The Deficit Reduction Act of 2005 directed
the Secretary of Health and Human Services to identify at least two
conditions that:
• Are high cost or high volume or both
• Could reasonably have been prevented through the application of
evidence-based guidelines
• Result in the assignment of a case to a Medicare Severity DiagnosisRelated Group (MS-DRG) that has a higher payment when present
as a secondary diagnosis
Inpatient Prospective Payment System (IPPS) hospitals were notified
that as of October 1, 2008, they would not receive the higher MS-DRG
payment for cases when one of the selected conditions is acquired
during hospitalization. In August 2008, CMS, in collaboration with
CDC, published the IPPS fiscal year 2009 final rule, which detailed
11 condition categories selected for implementation. Among these
are catheter-associated bloodstream infections, cathether-associated
urinary tract infections, and surgical site infections following coronary artery bypass graft, certain orthopedic procedures, or bariatric
surgery. Considered but not included were MRSA and C. diff. Since
CMS may revise the list from time to time, these infections may well
be added at a later date. For now, hospitals are required to submit
POA documentation for inpatient discharges with respect to the selected conditions. CMS has encouraged state Medicaid programs to
mirror its policies on payment for hospital-acquired conditions; New
York and Pennsylvania have already done so. Several large insurers
have followed suit as well.
The Joint Commission, which accredits hospitals and has the authority to deem that accredited hospitals satisfy Medicare’s Conditions of
Participation, has incorporated additional infection control expectations in both its accreditation standards and its 2009 national patient
safety goals. Standards relate to surveillance, prevention, control,
and documentation. The Joint Commission joined with three major infection control associations and the American Hospital Association to issue the above-referenced “Compendium of Strategies to

8

www.nhpf.org

ISSUE BRIEF

No. 830

Prevent Healthcare-Associated Infections in Acute Care Hospitals”
(see endnote 5).
National and state hospital associations have been active in education
campaigns and other infection control initiatives, as have the associations of infection preventionists and health care epidemiologists.

O n t he Prov i der Si de : Rep o r t i n g
At the individual hospital level, the flurry of measurement and reporting requirements from federal agencies, states, and associations
can be confusing. Some administrators, faced with scarce resources
and competing demands, understandably wish for convergence on
two points: this is what you do to make it stop, and here is what you
are required to report.
CMS’s POA reporting is seen as onerous by some hospitals; others see
it as a change whose time has come. The process requires a physician
to make a determination in each patient’s case as to whether certain
secondary diagnoses are present on admission, entailing more time
and often more tests than previously, and to write this down in a
form that can be recognized by a coder. (Proponents of surveillance
systems say this determination can be made fairly easily through
review of routine lab tests.) Moreover, CMS says, “Issues related to
inconsistent, missing, conflicting, or unclear documentation must be
resolved by the provider,” adding to the burden.17 Whether potential
withholding of payment is conducive to physicians and hospitals
working in tandem to satisfy the Medicare agency is perhaps open
to discussion.
The impact of the new CMS policy is also an open question. The effect on infection rates cannot yet be discerned. CMS has estimated
that the savings realized from denying higher payment for treatment of hospital-acquired conditions will be $21 million per year,18
which prompted one hospital official to comment that its value had
been oversold to policymakers and the public. Some analysts have
suggested that the chief effect of POA reporting is likely to be channeling hospital resources into proving that infections came from
somewhere else (the gym, perhaps).
Physicians have been less than enthusiastic about the inclusion of
infections on CMS’s no-pay list. Some have suggested that the list
should be limited to conditions for which adherence to evidence-based
9
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guidelines has been shown to eliminate occurrences. A bone of contention is CMS’s characterization of included infections as “reasonably preventable.” The American Medical Association (AMA) points
out that risk of infection varies with a patient’s underlying condition;
the organization would like the rules to account for patient risk factors and other issues largely beyond doctors’ control. The AMA has
requested that CMS factor the cost increases related to complying
with this program into the physician pay formula. Physicians have
also voiced the fear that what has started as a hospital-based proposition will move to the office practice next, as has already been the case
with other quality-reporting initiatives.19
Infection preventionists have been cautiously supportive of “tying
payment to conditions that have a high prevention rate and associated actionable evidence-based prevention guidelines.” However,
APIC believes that payment policy should recognize and encourage
institutions that are making progress in reducing infections.20

Reduci n g H A I s
Some hospitals and physician leaders have achieved dramatic reductions in infection rates and mortalities. When PHC4 began reporting
hospital infection statistics, and many hospitals cried foul, Hamot
Medical Center in Erie responded by investing in surveillance technology and developing new procedures that lowered its infection
rates. Another Pennsylvania institution often cited as an inspiring
example is Allegheny General Hospital (AGH) in Pittsburgh. Under
the leadership of Richard Shannon, MD, the AGH medical intensive care and coronary care units between 2003 and 2006 achieved
a greater than 90 percent reduction in central line–associated bloodstream infections (CLABSIs) and reduced CLABSI deaths to zero.
Other physicians have continued the work, ensuring that physicians
and nurses are trained in a standardized way of inserting and maintaining central lines, and have all but eliminated CLABSIs.21 Significant improvements have also been documented in places other than
Pennsylvania, at the level of hospitals, hospital departments, or in
some cases as a consortium of institutions. For example, the Greater
New York Hospital Association and the United Hospital Fund have
attracted 38 hospitals to a CLABSI collaborative; in its two years of
operation, CLABSI rates in participating hospitals have declined by
more than 70 percent.22
10
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Reachi n g Zero W hen ?
A conference sponsored by Cardinal Health (maker of MedMined)
in November 2008 was titled Chasing Zero. Speaker after speaker
agreed that zero infections was the only appropriate goal. What will
it take to get there?
Some have chosen a legislative strategy, particularly with respect to
MRSA. In addition to activity at the state level, bills in the U.S. House
of Representatives and the Senate would facilitate the exchange of best
practices, promote public education, mandate reporting, and make
further adjustments to Medicare payment.23 Infection preventionists
tend to favor federal support of research and evidence development
and to fear the enshrinement of current medical knowledge in statute. A January 2009 editorial in the journal Infection Control & Hospital
Epidemiology acknowledged that we have yet to attain “a clear understanding of which risk factors operate in which settings and which
interventions are more, or even most, likely to be successful.”24

We have yet to attain “a clear
understanding of which risk
factors operate in which settings
and which interventions are
more, or even most, likely to be
successful.”

As with any crusade, leadership is key to conquering infection. Under Chief Medical Officer Jonathan Perlin, MD, PhD, hospital giant
HCA (Hospital Corporation of America) initiated an aggressive antiMRSA campaign and adopted its own list of “serious preventable
adverse events” for which it will not bill. Acknowledging in the
course of a 2007 presentation that provider control is an issue, Dr.
Perlin said, “We can choose to argue about the 1-3% that’s outside
of our control or focus on the 97-99% that is within our control.”25 In
fact, leaders in the field agree that changing the cultural view of the
problem is at the heart of solving it. For many years, infections were
seen as part of the territory: they happened. Reaching zero requires
accepting that they do not have to happen.
The patient-safety consciousness-raising that followed the Institute
of Medicine’s 1999 report To Err is Human taught practitioners and
observers to look to system fallibility rather than blaming individual
clinicians. The Institute for Healthcare Improvement’s Donald Goldman, MD, closes the circle by suggesting that after a system’s design
is perfected and regularly monitored—for hand hygiene, say—individuals should be held accountable for failing to follow rules.26
At this stage, “perfected” is well beyond the reach of most hospitals,
and the incidence and severity of infections continues to escalate.
An APIC study released in November 2008 found that 13 of 1,000 patients were colonized with C. diff., considerably higher than previous
11
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incidence estimates.27 Similar estimates were found in a recent CDC
study. In addition to tracking MRSA and C. diff., CDC is tracking
other harmful bacteria, such as strains of Acinetobacter, which are not
yet common but are already drug-resistant.
The challenges are evident. So is the need to master them. If it can be
done in Hamot Medical Center or Allegheny General Hospital, is there
really an excuse to allow the bacteria to win anywhere else? As British entrepreneur Richard Branson has observed, if the airline industry had the “adverse event” track record of the hospital industry, “we
would have been grounded years ago.”28 Consumer groups have called
for greater employment of government oversight and mandates.29
Some experts say that a critical change already has occurred. In the
1970s, CDC’s Study on the Efficacy of Nosocomial Infection Control (SENIC) project found that hospitals could reduce their infection rates by approximately 32 percent if their infection surveillance
and control programs followed agency guidelines.30 The goal today
is a reduction to zero, but getting there will be a challenge. Policy
options for addressing research, education, training, payment, and
transparency as means to the goal are still being sorted out.
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